Acquired hypofibrinogenemia: Current perspectives

Journal of Blood Medicine

Volumn 7, Issue , 2016, Pages 217-225

  Besser, Martin W ^a   MacDonald, Stephen G ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Afibrinogenemia; Clauss fibrinogen assay; Direct oral anticoagulant; Dysfibrinogenemia; Fibrinogen antigen; Functional fibrinogen; Gravimetric fibrinogen assay; PT derived fibrinogen; Viscoelastic testing

Indexed keywords

DABIGATRAN; FIBRINOGEN; HIRULOG; VON WILLEBRAND FACTOR;

ARTICLE; DYSFIBRINOGENEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; GRAVIMETRY; HEMODILUTION; HUMAN; HYPOFIBRINOGENEMIA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THORAX SURGERY; THROMBOELASTOGRAPHY;

EID: 84992699547     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: 10.2147/JBM.S90693     Document Type: Article

References (48)

1. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005; 3(8): 1894-1904.
2. Collins PW, Solomon C, Sutor K, et al. Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. Br J Anaesth. 2014; 113(4): 585-595.
3. Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med. 2002; 126(4): 499-505.
4. Manco-Johnson MJ, Dimichele D, Castaman G, et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009; 7(12): 2064-2069.
5. Idris SF, Hadjinicolaou AV, Sweeney M, Winthrop C, Balendran G, Besser M. The efficacy and safety of cryoprecipitate in the treatment of acquired hypofibrinogenaemia. Br J Haematol. 2014; 166(3): 458-461.
6. Grottke O, Braunschweig T, Henzler D, Coburn M, Tolba R, Rossaint R. Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury. Crit Care. 2010; 14(2): R62.
7. Mackie IJ, Kitchen S, Machin SJ, Lowe GD. Guidelines on fibrinogen assays. Br J Haematol. 2003; 121(3): 396-404.
8. Macfarlane RG, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol. 1953; 6(1): 3-8.
9. Faraday N. Fibrinogen concentrate and allogeneic blood transfusion in high-risk surgery. Anesthesiology. 2013; 118(1): 7-9.
10. Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008; 93(10): 1488-1494.
11. Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004; 77(4): 331-335.
12. Rodeghiero F, Castaman G, Dini E. Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. Thromb Res. 1990; 57(1): 31-38.
13. Ludlam CA, Bennett B, Fox KA, Lowe GD, Reid AW. Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Blood Coagul Fibrinolysis. 1995; 6(3): 273-285.
14. Dear A, Brennan SO, Sheat MJ, Faed J, George PM. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain. Haematologica. 2007; 92(11): e111-e117.
15. Hammarsten O. Ueber das Fibrinogen I. Erster Abschnitt. Pfluegers Arch Ges Physiol. 1879; 19: 563-622.
16. Owen CA. History of Blood Coagulation. Roechester, MN: Mayo Clinic; 2001.
17. Mackie IJ, Kitchen S, Machin SJ, Lowe GD. Haemostasis, Thrombosis Task Force of the British Committee for Standards in H. Guidelines on fibrinogen assays. Br J Haematol. 2003; 121(3): 396-404.
18. Chitolie A, Mackie IJ, Grant D, Hamilton JL, Machin SM. Inaccuracy of the ‘derived’ fibrinogen measurement. Blood Coagul Fibrinolysis. 1994; 5(6): 955-957.
19. Besser MW, Klein AA. The coagulopathy of cardiopulmonary bypass. Crit Rev Clin Lab Sci. 2010; 47(5-6): 197-212.
20. Macdonald S, Bannister N, Ortmann E, et al. Determination of fibrinogen level to guide replacement therapy in patients undergoing cardiopulmonary bypass with direct thrombin inhibitors. J Thromb Haemost. 2013; 11(s3).
21. Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Haematol. 2016; 173(1): 37-48.
22. Ponschab M, Voelckel W, Pavelka M, Schlimp CJ, Schochl H. Effect of coagulation factor concentrate administration on ROTEM(R) parameters in major trauma. Scand J Trauma Resusc Emerg Med. 2015; 23: 84.
23. Harr JN, Moore EE, Ghasabyan A, et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock. 2013; 39(1): 45-49.
24. Solomon C, Fickenscher K, Ormonde L, Ranucci M. Validation of viscoelastic coagulation tests during cardiopulmonary bypass: comment. J Thromb Haemost. 2015; 13(12): 2279-2281.
25. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: A review of critical levels and replacement therapy. Transfusion. 2014; 54(5): 1389-1405; quiz 1388.
26. Hunt BJ, Allard S, Keeling D, et al. A practical guideline for the haematological management of major haemorrhage. Br J Haematol. 2015; 170(6): 788-803.
27. Kalina U, Stohr HA, Bickhard H, et al. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis. 2008; 19(8): 777-783.
28. Besser MW, Ortmann E, Klein AA. Haemostatic management of cardiac surgical haemorrhage. Anaesthesia. 2015; 70 Suppl 1: 87-95, e29-31.
29. Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia. 2015; 70(2): 166-175.
30. Leal-Noval SR, Casado M, Arellano-Orden V, et al. Administration of fibrinogen concentrate for refractory bleeding in massively transfused, non-trauma patients with coagulopathy: A retrospective study with comparator group. BMC Anesthesiol. 2014; 14: 109.
31. Pool JG. Cryoprecipitate in the treatment of hemophilia. Calif Med. 1970; 113(2): 66-67.
32. Cohn EJ, Oncley JL, Strong LE, Hughes WL, Armstrong SH. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. the characterization of the protein fractions of human plasma. J Clin Invest. 1944; 23(4): 417-432.
33. Yasunaga H. Risk of authoritarianism: fibrinogen-transmitted hepatitis C in Japan. Lancet. 2007; 370(9604): 2063-2067.
34. Bruynseels D, Solomon C, Hallam A, et al. Commentary on reconstituting fibrinogen concentrate to maintain blinding in a double-blind, randomized trial in an emergency setting. J Emerg Med. 2016; 50(1): 104-107 e101.
35. Galas FR, de Almeida JP, Fukushima JT, et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. J Thorac Cardiovasc Surg. 2014; 148(4): 1647-1655.
36. Idris SF, Hadjinicolaou AV, Sweeney M, Winthrop C, Balendran G, Besser M. Is the continued use of UK plasma sourced cryoprecipitate justified? Response to Makris. Br J Haematol. 2015; 168(6): 910-911.
37. Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost. 2016; 22(2): 109-114.
38. Hanna JM, Keenan JE, Wang H, et al. Use of human fibrinogen concentrate during proximal aortic reconstruction with deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2016; 151(2): 376-382.
39. Wikkelso AJ, Edwards HM, Afshari A, et al. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth. 2015; 114(4): 623-633.
40. Tanaka KA, Egan K, Szlam F, et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion. 2014; 54(1): 109-118.
41. Martini WZ, Dubick MA. Fibrinogen concentrate administration inhibits endogenous fibrinogen synthesis in pigs after traumatic hemorrhage. J Trauma Acute Care Surg. 2015; 79(4): 540-547; discussion 547-548.
42. Bolliger D, Tanaka KA. Haemostatic efficacy of fibrinogen concentrate: is it the threshold or the timing of therapy? Br J Anaesth. 2015; 115(2): 158-161.
43. Zentai C, Braunschweig T, Schnabel J, Rose M, Rossaint R, Grottke O. Fibrinogen concentrate does not suppress endogenous fibrinogen synthesis in a 24-hour porcine trauma model. Anesthesiology. 2014; 121(4): 753-764.
44. Martini J, Maisch S, Pilshofer L, Streif W, Martini W, Fries D. Fibrinogen concentrate in dilutional coagulopathy: A dose study in pigs. Transfusion. 2014; 54(1): 149-157.
45. Rahe-Meyer N, Solomon C, Winterhalter M, et al. Thromboelastometryguided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg. 2009; 138(3): 694-702.
46. National Institute for Health and Care Excellence. Detecting, Managing and Monitoring Haemostasis: Viscoelastometric Point-of-Care Testing (ROTEM, TEG and Sonoclot Systems). 2014. Available from: https://www.nice.org.uk/guidance/dg13. Accessed August 31, 2014.
47. Aubron C, Reade MC, Fraser JF, Cooper DJ. Efficacy and safety of fibrinogen concentrate in trauma patients-a systematic review. J Crit Care. 2014; 29(3): 471 e411-477.
48. Wafaisade A, Lefering R, Maegele M, et al. Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge. J Trauma Acute Care Surg. 2013; 74(2): 387-383; discussion 393-385.